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Aldehyde dehydrogenase 1a3 defines a subset
of failing pancreatic b cells in diabetic mice
Ja Young Kim-Muller1,*, Jason Fan1,2,*, Young Jung R. Kim2, Seung-Ah Lee1, Emi Ishida1, William S. Blaner1
& Domenico Accili1
Insulin-producing b cells become dedifferentiated during diabetes progression. An impaired
ability to select substrates for oxidative phosphorylation, or metabolic inflexibility, initiates
progression from b-cell dysfunction to b-cell dedifferentiation. The identification of pathways
involved in dedifferentiation may provide clues to its reversal. Here we isolate and functionally
characterize failing b cells from various experimental models of diabetes and report a striking
enrichment in the expression of aldehyde dehydrogenase 1 isoform A3 (ALDHþ ) as b cells
become dedifferentiated. Flow-sorted ALDHþ islet cells demonstrate impaired glucose-
induced insulin secretion, are depleted of Foxo1 and MafA, and include a Neurogenin3-
positive subset. RNA sequencing analysis demonstrates that ALDHþ cells are characterized
by: (i) impaired oxidative phosphorylation and mitochondrial complex I, IV and V;
(ii) activated RICTOR; and (iii) progenitor cell markers. We propose that impaired
mitochondrial function marks the progression from metabolic inflexibility to dedifferentiation
in the natural history of b-cell failure.
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D
iabetes arises as a consequence of combined abnormalities
in insulin production and function1. Although alterations
in either arm of this homeostatic loop can result in
full-blown disease, in most individuals, the two abnormalities
coexist. While target organs show an impaired response to insulin
(so-called insulin resistance), b-cells of diabetics show a blunted
and mistimed response to nutrients2. During the natural history
of the disease, b-cell function markedly deteriorates3. In fact, an
intrinsic susceptibility of the b cell to functional exhaustion-
commonly referred to as ‘b-cell failure’-sets apart individuals who
go on to develop diabetes from those that, at the same level of
insulin resistance, do not3. Abnormalities of islet cell function in
diabetes include an impaired insulin response to stimulus,
a reduced number of b cells, and an inappropriate glucagon
response4. This occurs despite the fact that reversal of
hyperglycemia can partly restore b-cell function, even in
patients with advanced disease5. Treatments range from
preserving b-cell function by reducing the metabolic demand
on b-cells, to increasing b-cell performance to meet the increased
metabolic demand2. Notwithstanding this evidence, it is unclear
whether the two primary components of b-cell failure, impaired
insulin secretion and reduced b-cell mass, are mechanistically
linked. We have shown that genetic ablation of Foxo function in
b-cells impairs metabolic flexibility, that is, the ability to switch
from glucose to lipids as a source of acetyl-CoA for mitochondrial
oxidative phosphorylation, paving the way for b-cell
dedifferentiation6–9. These two processes bookend b-cell failure,
but we do not know what happens in between.
To address this question it’s necessary to first discover
biomarkers that can be used to isolate and characterize ‘failing’
b cells. In this study, we report the discovery of an isoform of the
enzyme aldehyde dehydrogenase 1 isoform A3 (ALDH1A3) as a
biomarker of dysfunctional b cells. We isolated and characterized
ALDH1A3-expressing islet cells, and compared their gene
expression profiles in normal and diabetic mice. The data
indicate that two reciprocal processes unfold in failing b cells: a
decrease of mitochondrial function with presumptive activation
of RICTOR, likely compensatory in nature, associated with
progenitor cell-like features. We identify a narrow set of
candidate genes that may affect the transition from a healthy to
a dysfunctional b cell. The significance of this work consists in the
discovery of a biomarker of b-cell dysfunction that can also be
used to isolate failing cells; and in the identification of a
pathogenic mechanism and a narrow set of potential effectors
that can be tested for therapeutic relevance.
Results
Elevated ALDH1A3 is a common feature of diabetic b cells. We
reasoned that critical changes in gene expression during b-cell
failure would be shared across multiple models of diabetes. We
used two permutations of a genetic approach involving triple
Foxo knockouts (Foxo1, 3a and 4) at two distinct developmental
stages: (i) in pancreatic precursors (generated using Pdx1-cre-
mediated gene knockout)9; (ii) in terminally differentiated b cells
(generated using Ins-cre)7. The triple Foxo knockout faithfully
replicates human MODY, a genetic form of diabetes caused
by an intrinsic b-cell abnormality10. When we compared
transcriptomes of islets from these models, a narrow selection
of genes was uniformly affected across the board. Among them
was ALDH1A3, expression of which increased three to sixfold
with robust adjusted P values (Table 1). We tested the expression
of ALDH1A3 in other models of diabetes including aging,
diet-induced and db/db mutants, and found it to be increased
too (Fig. 1a). We sought independent confirmation of this
observation in the literature, and found that similar increases of
ALDH1A3 had been observed in diabetic Nkx6.1 (ref. 11) and
MafA knockout mice12, as well as in a cross of diabetes-sensitive
versus resistant mice13. ALDH1A3 is notably absent from normal
b cells14. In a recent study inspired by these findings, we found
that ALDH1A3 is also elevated in islets from patients with type 2
diabetes15.
ALDH1A3 had two attractive features that justified further
studies: ALDH1 activity marks human cancer progenitor
cells16–19, and ALDH1A3 has been recognized as the isoform
conveying increased ALDH1 activity in lung, ovary, breast, head
and neck cancer and melanoma20–22. This observation is
consistent with the notion that dedifferentiating b cells have
progenitor-like features11,23,24. Moreover, ALDH-expressing cells
can be readily isolated using live cell assays25. ALDH1A3 is one of
20 murine genes encoding NAD(P)þ -dependent enzymes that
catalyse aldehyde oxidation. ALDHs also have additional catalytic
(for example, esterase and reductase) and non-catalytic activities.
ALDH1A3 is also known as retinaldehyde dehydrogenase
(RALDH3) owing to its ability to synthesize retinoic acid (RA)
from retinal.
The increase was specific to ALDH1A3, as other isoforms
showed little if any change (Fig. 1a). Measurements of all-trans-
RA and 9-cis-RA production in islets confirmed a correlation
between ALDH1A3 levels and RA generation, indicating that the
enzyme is catalytically active (Fig. 1b,c). We localized ALDH1A3
in islets using immunohistochemistry. ALDH1A3-positive cells
were rare in normal islets (Fig. 2a). We studied a classic model of
diabetes secondary to extreme obesity, db/db mice, as well as mice
that develop diabetes as a consequence of extreme peripheral
insulin resistance, brought about by targeted knockout of
insulin receptor in muscle, fat and brain (GIRKO)26. Of note,
the latter mice are lean and have no intrinsic b-cell abnormalities,
but develop diabetes as a result of their inability to compensate
for insulin resistance. In both models, the number of ALDH1A3-
expressing cells rose considerably (Fig. 2a,b). There was
heterogeneity of immunohistochemical signal intensity among
ALDH1A3-expressing cells. We empirically defined them as
ALDH1A3low and ALDH1A3hi cells. ALDH1A3 immuno-
reactivity showed a reciprocal pattern with insulin immuno-
reactivity such that ALDH1A3hi cells were insulin-negative, while
ALDH1A3low cells retained some insulin immunoreactivity
(Fig. 2a,b). We did not detect strongly insulin-immunoreactive
cells that were also ALDH1A3-positive, nor did we detect any
other endocrine cell type that co-localized with ALDH1A3 in
mouse islets (Fig. 2b). These data show that ALDH1A3-positive
cells are heterogeneous and are comprised of insulin-producing
cells, as well as hormone-negative cells that can potentially
represent a progenitor-like population.
We tested the expression of various b-cell markers in
ALDH1A3-positive cells. They had weak MafA immunoreactivity
(Fig. 2c), but retained Pdx1 immunoreactivity (Fig. 2d). Nkx6.1
was generally reduced in ALDH1A3-positive cells (Fig. 2e), with
Nkx6.1 absent in a subset of B10% ALDH1A3-positive cells
(Fig. 2e, right panels, white arrows). We also examined two
progenitor cell markers, L-myc and Neurogenin3. Consistent with
previous results, we found that L-myc expression increased in
Foxo knockout islets and that ALDH1A3-positive cells were
L-myc-positive (Fig. 2f). Moreover, there was a subset of
ALDH1A3þ /Neurog3þ cells (Fig. 2g, white arrows). In Foxo
knockout islets, ALDH1A3þ /Neurog3þ cells accounted for 5.2%
of ALDH1A3þ cells (7/134, n¼ 9 sections from 3 mice) while in
wild-type islets, we found no Neurog3þ cells and hence no
ALDH1A3þ / Neurog3þ cells. The staining method was
validated in E12.5 fetal pancreas sections containing endocrine
progenitors (Supplementary Fig. 1). These data provide
immunohistochemical evidence that ALDH1A3 marks a
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heterogeneous cell population, with features of incipient b-cell
failure (reduced insulin), and includes a subset of dedifferentiat-
ing (low MafA or Nkx6.1) or dedifferentiated cells (L-myc and
Neurog3-expressing)7,11,24.
ALDH1A3 overexpression does not impair insulin secretion.
As Foxo1 loss-of-function is associated with increased ALDH1A3
levels, we asked whether Foxo1 regulates ALDH1A3 in MIN6
insulinoma cells. We transfected wild-type and two different
mutant Foxo1 constructs to investigate this point. The first
mutant is a dominant-negative that binds to DNA but lacks the
transactivation domain, preventing binding of RNA polymerase,
hence transcription. When overexpressed, it outcompetes
endogenous Foxo (1, 3a and 4) and effectively mimics the effect of
a knockout27. The second mutant, DNA-binding deficient, does
not bind to DNA, and fails to activate Foxo targets for which
DNA binding is required28. Inhibition of Foxo1 by the dominant-
negative mutant resulted in a B30-fold increase in Aldh1a3
messenger RNA (mRNA), while the DNA-binding deficient
mutant Foxo1 failed to activate Aldh1a3 expression (Fig. 3a). This
experiment shows that Foxo1 inhibits Aldh1a3 independently of
DNA binding, likely acting as a co-repressor28,29. These data are
consistent with the possibility that activation of ALDH1A3
expression is an early correlate of reduced Foxo1 function.
Reduced RA signalling in islets has been linked to defective
insulin secretion30. To test whether elevated ALDH1A3 activity
affects b-cell function, we overexpressed ALDH1A3 in MIN6 cells
using either transient transduction with adenovirus (Fig. 3b) or
the derivation of stably transfected clones, and then measured
expression of genes that are important for b-cell function or
glucose-stimulated insulin secretion. In either case, we found no
defects in gene expression (Fig. 3c) or insulin secretion (Fig. 3d).
Moreover, we transduced islets of wild-type C57Bl/6J mice
with ALDH1A3 adenovirus and found a small, but statistically
significant increase of glucose-induced insulin secretion (Fig. 3e).
ALDH1A3 activity can be inhibited by the irreversible inhi-
bitor N,N-diethylaminobenzaldehyde25. We performed insulin
secretion experiments in MIN6 cells overexpressing ALDH1A3,
in the presence of N,N-diethylaminobenzaldehyde. But we didnot
detect an effect of this compound to change insulin secretion
(Fig. 3f). Finally, we measured oxygen consumption in MIN6 cells
overexpressing ALDH1A3 as a surrogate of mitochondrial
function, and found a modest decrease (Fig. 3g). However, in
light of the fact that insulin secretion was normal (in MIN6) or
slightly elevated (in primary islets), we suppose that this slight
oxidative defect is unlikely to result in a functional change. These
data showing that acute gain-of-function of ALDH1A3 doesnot
compromise b-cell function suggest that ALDH1A3 is a marker,
rather than a cause of b-cell dysfunction.
Isolation and characterization of ALDH1A3-expressing islet cells.
We used a vital assay of ALDH activity to isolate ALDH1A3-
expressing cells from mouse islets (Fig. 4a). The cell-permeable
fluorescent ALDH substrate BODIPY-aminoacetaldehyde (alde-
flour) is metabolized to the non-releasable derivative
BODIPY-aminoacetate (BAA), thus permanently labelling
Table 1 | Comparison of the top ten transcripts in two models of Foxo knockout b cells.
b-cell-specific triple FoxO knockout (Rip-cre) Pan-pancreatic triple FoxO knockout (Pdx-cre)
Gene symbol RefSeq P Fold change Gene symbol RefSeq P Fold change
Serpina7 NM_177920 0.0057 6.10 Serpina7 NM_177920 0.005 11.23
Rsl1 NM_001013769 0.0645 4.99 Penk NM_001013769 1.45 10 5 9.24
Tcea1 NM_011541 0.0804 4.72 Aldh1a3 NM_053080 5.18 10 7 5.59
Ly96 NM_016923 0.0210 3.54 Aass NM_013930 0.0008 5.29
Asb11 NM_026853 0.0011 2.93 Rsl1 NM_001013769 0.0645 4.63
Tc2n NM_001082976 0.0428 2.91 Fabp3 NM_010174 0.0070 3.49
Aldh1a3 NM_053080 5.18 10 7 2.87 Zfp423 NM_033327 5.70 106 3.40
Fabp3 NM_010174 0.0070 2.70 Ly96 NM_016923 0.0210 3.39
Bet1 NM_009748 0.0558 2.69 Asb11 NM_026853 0.0011 3.36
Naa38 NM_133939 0.04334 2.68 Tmed6 NM_025458 0.0097 3.29

















































Figure 1 | Increased levels and activity of ALDH1A3 in diabetic mice.
(a) Western blot of ALDH1A3 in islets isolated from different models of
wild-type and diabetic mice. The lower molecular weight band in young
(3-month-old) mice is a non-specific band commonly observed with
Aldh1a3 immunodetection. (b,c) All-trans (b) and 9-cis retinoic acid (c) in
whole pancreas of control and diabetic mice. Shaded bars: db/db mice and
their wild-type controls. Filled bars: Pdx-cre Foxo knockout mice and their
wild-type controls (n¼ 5 for each group). One asterisk indicates Po0.05
by one-way ANOVA. Error bars indicate s.e.m.
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ALDH-expressing cells. We used red fluorescent protein (RFP) to
label b (or former b) cells by cre-mediated recombination7.
Thereafter, we incubated cells with aldefluor, and selected for RFP
(red) and aldefluor (green) fluorescence, yielding ALDH and
ALDHþ cells. The latter should include dysfunctional/
dedifferentiating b cells. In wild-type mice, we obtained three sub-
populations: RFPALDH (non-b cells), RFPþALDH (healthy
b cells), and RFPþALDHþ (dysfunctional b cells) (Fig. 4b). The
latter represented o1% of total cells in normal islets. In separate





















































































Figure 2 | Localization of ALDH1A3 in mouse islets. (a) ALDH1A3 immunoreactivity in islets from normal and diabetic GIRKO mice.
(b) Co-immunostaining of ALDH1A3 and insulin or glucagon, somatostatin (Sms), and Pp in db/db, GIRKO, and Pdx1-cre-driven Foxo knockout mice.
(c–e) Co-immunostaining of ALDH1A3 with MafA (c), Pdx1 (d), or Nkx6.1 (e). ALDHþ/Nkx6.1 cells are indicated by the white arrows. MafA/ALDH1A3
(c) immunohistochemistry was performed on consecutive sections, whereas Pdx1/ALDH1A3 and NKX6.1/ALDH1A3 immunohistochemistry
was performed on the same section. (f,g) Co-immunohistochemistry of ALDH1A3 with progenitor cell markers, L-myc (f) and neurogenin3 (g).
ALDH1A3þ / Neurog3þ cells are indicated by the white arrows. Neurog3/ALDH1a3 immunohistochemistry was performed on consecutive sections.
To better assess Neurog3/ALDH1A3-positive cells, we provide two representative sections from Foxo knockout mice. Scale bar, 100mM in (a,c), scale bar,
50mM in (d–g). In (b) left panel scale bar, 100mM, right panel scale bar, 50mM. DAPI, 4,6-diamidino-2-phenylindole.
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cell-specific (Rip-cre) triple Foxo1 knockouts8. As predicted, the
RFPþALDHþ sub-population increased about sevenfold in this
model (Fig. 4c,d).
We performed a preliminary characterization of ALDH and
ALDHþ cells by measuring insulin secretion and gene expres-
sion. The predicted outcome of these experiments was that
ALDHþ cells would be: (i) enriched in ALDH1A3; (ii) impaired
in their ability to secrete insulin; (iii) depleted of markers of
functional b cells, including Foxo1 (ref. 8). All predictions were
borne out by the data. In glucose-stimulated insulin release
experiments using ALDH versus ALDHþ cells, we found that
only the former responded to glucose, providing critical evidence
for a functional impairment of ALDHþ cells (Fig. 4e). Aldh1a3
mRNA was restricted to the RFPþALDHþ population in both
wild-type and triple Foxo knockout mice (Fig. 4f). Foxo1 was
reduced byB70% in ALDHþ cells from wild-type mice (Fig. 4g).
Glucokinase was nearly equally represented in all fractions, but
was decreased in ALDHþ cells of triple Foxo knockouts (Fig. 4h),
similar to previously reported single knockouts7. Insulin2 and
Nkx6.1 expression were greatly enriched in the RFPþ population,
while glucagon and somatostatin were enriched in the RFP
population (Fig. 4i–l), providing another key element to support
the identity of these cells. Foxo1 target MafA was enriched
in the RFPþALDH population and drastically reduced in
RFPþALDHþ cells. These data are consistent with the notion
that ALDHþ cells are b cells that have lost key functional
features (Fig. 4m). Finally, Glut2 expression was restricted to
















































































































Figure 3 | ALDH gain-of-function in b cells. (a) Effect of Foxo1 overexpression on Aldh1a3 mRNA in Min6 cells. Foxo-DN is a truncated mutant that is
unable to drive gene expression and competes with endogenous Foxo for DNA binding. Foxo- DNA-binding deficient (DBD) is a mutant unable to bind the
Foxo response element, but can still function as a coregulator of gene expression28. (b) Western blot analysis of ALDH1A3 levels following lentiviral
transduction in MIN6 cells. (c) Gene expression in Min6 cells stably expressing GFP or ALDH1a3. (d) Insulin secretion expressed as fold-increase from 5 to
20mM glucose in MIN6 cells expressing either GFP or ALDH1A3 (n¼ 8). (e) Insulin secretion in MIN6 cells stably transfected with ALDH1A3 (n¼ 3).
(f) Insulin secretion (expressed as in panel d) in islets isolated from db/db mice and their wild-type controls following treatment with the ALDH inhibitor
N,N-diethylaminobenzaldehyde (DEAB) at the doses indicated (n¼4). Each experiment was performed with pooled islets from 5 mice per genotype.
(g) Area under the curve of oxygen consumption rates measured in Min6 cells stably expressing either GFP or ALDH1A3 (n¼4 per group). One asterisk
indicates Po0.05 by one-way ANOVA. Error bars indicate s.e.m.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12631 ARTICLE
NATURE COMMUNICATIONS | 7:12631 | DOI: 10.1038/ncomms12631 | www.nature.com/naturecommunications 5
significantly decreased in Foxo knockouts, consistent with prior
findings (Fig. 4n)7.
Transcriptome of ALDHþ cells and progression of b-cell
failure. We carried out RNA sequencing analyses comparing
ALDHþ with ALDH b cells (RFPþ ), as well as other islet cell
types (RFP ) in wild-type mice. Moreover, we compared
wild-type ALDHþ cells with triple Foxo-deficient ALDHþ cells
generated by knocking out Foxo in mature b cells8. As a quality
control, we interrogated expression of all 20 Aldh transcripts, and
found that only Aldh1a3 showed differential expression in the
ALDHþ population (Fig. 5a). Moreover, in all comparisons
between ALDHþ and ALDH cells, Aldh1a3 was among the top
differentially expressed genes (Supplementary Tables 1 and 2).
This finding confirms the specificity and robustness of the
enrichment technique.
First, we analysed differences in the levels of individual
transcripts expressed in ALDHþ versus ALDH cells of wild-
type mice. Using Po0.05 adjusted for multiple comparisons as
threshold, we found 671 differentially expressed transcripts. A
complete list is shown in Supplementary Table 1 and a curated
sub-list in Supplementary Table 2. The transcripts fell into three
broad categories: terminal differentiation of b cells, mitochondrial
oxidative phosphorylation and ribosomal subunits. ALDHþ cells
were depleted of transcripts encoding insulin, IAPP, Cpe,
transthyretin, as well as other pancreatic hormones commonly
found at low levels in b cells31, and were enriched in transcripts
encoding markers of uncommitted endocrine progenitors,
such as Pax6, Rfx6, Rfx7, Mlxipl, as well as transcription factors
associated with progenitor cell differentiation, such as Ncor,
Hic1 and Bach2. Next, there was a striking decrease of selected
mitochondrial components: B30% of complex I NADH
dehydrogenase subunits (13 of 41), complex IV cytochrome C
oxidase subunits (8 of 25), and complex V F1 ATP synthase
subunits (15 of 54) were substantially decreased. In addition,
B30% of genes (28 of 92) encoding ribosomal 40S and 60S
subunits were coordinately decreased (Supplementary Tables 1
and 2). Interestingly, 6 of the top 12 differentially expressed
transcripts were long noncoding RNAs that have been associated
with b-cell dysfunction: Malat1, Neat1, Meg3, Peg3, Sngh11 and
Kcnq1ot1 (refs 32,33). These highly abundant transcripts increased
from 2.5- to 12-fold in ALDHþ cells (Supplementary Table 2).
We used the ‘upstream regulator analysis’ function of the
Ingenuity Analysis program to identify contributors to the
phenotype of ALDHþ cells based on coordinated changes
affecting their downstream effectors and regardless of whether
the regulator’s own expression levels changed. Z-scores were used
to predict activation or inhibition of individual networks8.


























































































































































































Figure 4 | Isolation and characterization of ALDHþ cells. (a) Enrichment procedure to isolate ALDH-expressing islet cells. b cells are labelled red by
Rip-cre-activated Tomato. Cells are incubated with aldefluor, and selected for tomato and aldefluor, yielding ALDH (low) and ALDHþ (high) cells.
(b,c) Experimental validation. Islets from 6-month-old b-cell-specific (Rip-cre) Foxo knockouts and littermate controls were sorted as described. The
different circles denote the three cell populations used in further studies: RFPALDH , RFPþALDH and RFPþALDHþ . (d) Quantification of
RFPþALDHþ cells in repeated sorts (n¼ 5) of wild-type and Rip-Foxo knockout animals. (e), Insulin secretion in RFPALDH (GFP_FITC, PE TR subset
2), RFPþALDH (GFP_FITC, PE TR subset), and RFPþALDHþ (GFP_FITC, PE TR subset 1) cells isolated from wild-type mice (n¼ 3). (f–n) Quantitative
PCR analysis of selected transcripts in the different fractions isolated from islet cell preparations. One asterisk indicates Po0.05 by one-way ANOVA.
Error bars indicate s.e.m.
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ALDHþ and ALDH cells could be subsumed under
mitochondrial oxidative phosphorylation and revealed a strong
potential activation of the RICTOR branch of mTOR signalling.
Importantly, the same top five pathways were altered in ALDHþ
cells isolated from wild-type and triple Foxo knockout mice,
confirming that most differences between wild-type and
Foxo-deficient ALDHþ cells are of a quantitative, rather than
qualitative nature (Table 2).
Transcription factor network analyses indicated that ALDHþ
cells have stem/progenitor cell properties, based on the
combination of activated GATA, Wnt, Nanog and Neurog3
(ref. 34) and decreased Foxo and Notch signalling (Table 3 and
Supplementary Table 3). Of note was also the marked inhibition
of two master regulators of mitochondrial biogenesis and
function, NFE2L2 and NRF1. NRF1 activates expression of
EIF2A1 as well as genes required for mitochondrial biogenesis,
function and mitochondrial DNA transcription35. The inhibition
of NRF1 is consistent with the decrease of Tfam and Eif2
signalling in ALDHþ cells (Supplementary Table 3). NFE2L2 is
involved in NRF2-mediated oxidative stress and unfolded protein
response36.
This analysis also indicated activation of RICTOR (mTORC2)
signalling. RICTOR promotes b-cell growth and insulin
secretion37. However, other features of ALDHþ cells suggest
that the activation of RICTOR is compensatory in nature.
For example, ATF4-mediated signalling is inhibited, thus leading
to decreased unfolded protein response and apoptotic signalling
in response to endoplasmic reticulum stress. There are
impairments in insulin and IGF1 receptor signalling, as well as
inhibition of the transcriptional network overseen by nuclear
receptor NR4A3, which is required for b-cell growth
(Supplementary Table 3)38. The decrease in insulin/IGF
receptor signalling is consistent with the homeostatic role of
Foxo in these pathways, such that low Foxo would be expected to
result in impaired insulin/IGF receptor signalling39. In addition,
the mild activation of Src and EGF receptor signalling observed in
ALDHþ cells suggests that cells are shifting from a fully
differentiated phenotype maintained through insulin receptor/
Foxo signalling, to a less differentiated phenotype dependent on
oncogene signalling with features of progenitor cells
(Supplementary Table 3).
Two other features of ALDHþ cells deserve mention: the
decrease in estrogen receptor signalling, and activation of
ALDH– ALDH+


































































































Figure 5 | Comprehensive analysis of ALDH isoform expression in
flow-sorted ALDHþ and ALDH cells. (a) Data from RNA sequencing of
all ALDH transcripts are represented as column Z-scores, with red
indicating high expression and blue indicating low expression. Each row
represents a different ALDH isoform, and each column an individual sample
used for analysis. RFPþALDH : JD001 through JD014, and RFPþALDHþ :
JD003 through JD015. Aldh1a3 is boxed for reference. (b) Model of the
relationship between changes in Foxo levels and gene expression signature
of ALDHþ cells.
Table 2 | Pathway analysis of RNA sequencing in wild-type
and Foxo knockout b cells.
P
Wild-type ALDH versus ALDHþ
Oxidative phosphorylation 8.58E 27
Mitochondrial dysfunction 1.02E 23
EIF2 signalling 1.31E 15
mTOR signalling 1.81E 10
Regulation of eIF4 and p70S6K signalling 7.17E 10




Regulation of eIF4 and p70S6K signalling 1.05E04
mTOR signalling 3.78E04
The table summarizes top pathways from transcriptome analysis of ALDH versus ALDHþ
cells.
Table 3 | Progenitor-like features of ALDHþ cells.
Transcription factor Z-score P
GATA4 2.607 1.00 10 1
GATA6 2.111 1.00 10 1
NKX6.1 1.969 2.68 10 2
PDX1 1.575 2.11 10 6
NANOG 1.508 1.62 10 2
GLIS3 1.384 8.57 104
CTNNB1 1.366 2.66 10 2
HNF1A 1.028 1.39 10 2
NEUROD1 0.741 4.70 104
NEUROG3 0.791 1.38 104
RBPJ  2.130 1.00 10 1
FOXO1  1.811 4.91 10 3
FOXO3  1.400 2.92 10 3
FOXO4 0.640 1.87 10 2
HNF4A  1.212 1.39 10 2
NKX2.2  1.000 2.65 104
Z-score analysis of transcriptional networks involved in pancreas development in ALDHþ cells.
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inflammation pathways, including NFKB1, MYD88, TICAM1,
IFRD1, TLR7, CXCL12 and IL6 (Supplementary Table 3).
Comparing wild-type and Foxo knockout ALDHþ cells. Next,
we compared ALDHþ cells from wild-type and triple
Foxo-deficient mice. The rationale was threefold: first, although
ALDH1A3 expression is a marker of reduced Foxo activity, Foxo
is not absent in the majority of these cells, and complete Foxo
ablation may exacerbate their phenotype; second, it may reduce
heterogeneity of ALDHþ cells; and third, because Foxo-deficient
mice develop a MODY-like form of diabetes, this comparison
might reveal qualitative differences between ALDHþ cells
isolated from euglycemic versus diabetic animals. One can
hypothesize that complete genetic ablation of Foxo mimics the
final stages in the progression of the fate of ALDHþ cells
and that, by analysing differences between wild-type and
Foxo-deficient ALDHþ cells, it’s possible to identify genes that
mark the mechanistic progression to an advanced phase of
cellular failure, or a tipping point towards dedifferentiation
(Fig. 5b).
When we compared transcriptomes of wild-type versus triple
Foxo knockout ALDHþ cells, we found few differentially
expressed genes, as predicted (A partial list is in Table 4 and a
complete list in Supplementary Table 4). The dearth of
differences between wild-type and Foxo-deficient ALDHþ cells
is wholly consistent with the concept that in diabetes there is a
‘spontaneous’ loss of Foxo6–8, and that Foxo normally restrains
ALDH1A3 expression (Fig. 3a). Nonetheless, these genes
indicated potential pathogenic processes unfolding in failing
b cells. A striking aspect of the gene expression profile of
Foxo-deficient ALDHþ cells is the decrease in Cyb5r3. This gene
encodes cytochrome b5 reductase isoform 3, one of four b5
reductase subunits (r1 through 4). Its expression is regulated by
Foxo and Nrf, consistent with our findings40. Cyb5r3 has a
membrane-bound and a soluble form, the latter of which is
restricted to erythrocytes. It utilizes NADH and NADPH to
synthesize long-chain FAs, and it’s also required for
mitochondrial complex III function. Cyb5r3-deficient cells show
decreased NADþ /NADH ratios, mitochondrial respiration rate,
ATP production and mitochondrial electron transport40. Notably,
knockout of the related isoform Cyb5r4 causes early-onset b-cell
failure in mice independent of peripheral insulin sensitivity41.
Other interesting genes that are specifically altered in
Foxo-deficient ALDHþ cells include: Elovl6, Ndor and Cyp27b1.
Elovl6 is a long chain fatty acid elongase that has an important
role in liver42. In b cells, its expression pattern mirrors Cyb5r3,
and can potentially act in concert with the latter to synthesize
long-chain FA. Similarly, the NAPDH-dependent oxidoreductase
Ndor, whose expression levels track closely those of Foxo in
ALDHþ cells, could be involved in mitochondrial processes
related to Cyb5r3. Cyp27b1 is required for the synthesis of
1,25-OH vitamin D3, and evidence suggests that it participates in
b-cell dysfunction in diabetes43. Finally, there were two
transcripts that showed opposite changes in wild-type versus
Foxo-deficient ALDHþ cells: the lncRNA Peg3, a parentally
imprinted transcript whose methylation correlates with human
islet function44, and Bach2, a transcription factor that has been
implicated in type 1 diabetes susceptibility45,46, as well as b-cell
stress47 (Table 4 and Supplementary Table 5).
Discussion
The key finding of this work is the identification of a
subpopulation of ALDHþ islet b cells. Based on their impaired
insulin secretory properties and transcriptional signature,
we propose that ALDHþ cells are failing b cells. They
show conjoined features of the two cardinal processes bookending
b-cell failure: mitochondrial dysfunction8 and progenitor-like
features7. We propose the following model (Fig. 5b): when b cells
are subject to increased demand for insulin production,
they increase cellular metabolism and substrate flux through
mitochondria. Foxo is activated to maintain normal oxidative
function and prevent cellular overwork6,7. The tradeoff of
Table 4 | Top 25 differentially expressed transcripts in ALDHþ cells from wild-type and Foxo knockout mice.
Gene Wild-type Foxo knockout Fold Change Log2 fold change P Adjusted P
Foxo1 1005.01 131.37 0.13  2.94 2.23E-11 3.47E-07
Cyb5r3 5076.01 1742.73 0.34  1.54 8.29E-09 6.46E-05
Cyp27b1 206.80 4.83 0.02  5.42 5.10E-07 0.002649712
Elovl7 384.62 38.27 0.10  3.33 1.46E-06 0.005684329
Hip1r 1463.56 467.44 0.32  1.65 2.98E-06 0.009288892
Bach2 211.79 11.73 0.06 4.17 2.45E-05 0.052959279
Ctsl 2272.77 5237.71 2.30 1.20 3.39E-05 0.052959279
Etl4 1573.45 590.80 0.38  1.41 3.21E-05 0.052959279
Muc4 3932.14 763.76 0.19  2.36 3.32E-05 0.052959279
Ptprt 753.26 181.42 0.24  2.05 2.71E-05 0.052959279
Dnahc17 112.89 1.32 0.01 6.41 3.87E-05 0.054903167
Spp1 3933.14 1896.47 0.48  1.05 0.000104638 0.136037989
Gpc6 72.93 0.00 0.00 NA 0.000119737 0.14369393
Cxcl13 71.93 0.00 0.00 NA 0.000135081 0.150528447
Prnd 93.91 1.06 0.01 6.47 0.000149671 0.155667934
2010015L04Rik 249.75 32.76 0.13  2.93 0.000188906 0.173360099
Ncam1 2471.57 1148.98 0.46  1.11 0.000183578 0.173360099
Jam2 437.57 97.38 0.22  2.17 0.000207049 0.179454216
Galntl4 316.69 53.81 0.17  2.56 0.000328609 0.269822705
D0H4S114 613.40 190.91 0.31  1.68 0.000492415 0.351638321
Hcn1 76.92 0.60 0.01  7.01 0.000495868 0.351638321
Nog 61.94 0.00 0.00 NA 0.000451442 0.351638321
Cox6b1 229.77 695.81 3.03 1.60 0.000553818 0.362501015
Krba1 424.58 108.79 0.26  1.96 0.000565259 0.362501015
NA, not applicable.
This table lists a subset of genes differentially expressed between wild-type and triple Foxo-deficient ALDHþ cells, arranged by P value.
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increased Foxo function is increased Foxo degradation6, leading
to eventual loss of the protein. As Foxo levels decline, ALDH1A3
is activated; thus, elevated levels of ALDH1A3 are a harbinger of
b-cell failure. In the progression of the cellular pathology,
mitochondrial complex I, IV and V functions are impaired,
leading to reduced ATP production, stalling of protein translation
and reactivation of genes that sustain a cellular progenitor
program. When Foxo levels reach their nadir (a situation
phenocopied by genetic knockout of Foxo), a further subset of
genes becomes altered, including Cyb5r3, Elovl6 and Bach2
(Fig. 5b). We propose that these genes have a pathogenic role in
b-cell dedifferentiation. Further studies to test their involvement
in this process are underway, with the expectation that they are
key mediators of progression of b-cell failure, and with the
ultimate goal of developing therapeutic approaches to ameliorate
b-cell dysfunction based on this model.
The role of ALDH1A3 in b-cell failure will have to be
determined through further studies. In oncology, there is no
consensus on whether ALDH1A3 is a marker or a pathogenic
factor in cancer progression18. Our data indicate that ALDH1A3
overexpression does not untowardly affect b-cell function, but
these experiments don’t capture the complexity of the potential
roles of ALDH1A3 in b-cell failure. For example, ALDH1A3
could promote mitochondrial dysfunction-the paramount feature
of ALDHþ cells-by activating RAR/RXR signalling via RA
production. This can result in increased Ppara function, a feature
of metabolically inflexible b cells8. This effect may require a
specific duration or additional contributors, and would have gone
undetected in the experiments carried out so far. To address this
and other possibilities, we are generating appropriate models of
loss- and gain-of-function.
A prominent aspect of the gene expression profile of ALDHþ
cells is the extent of impairment of mitochondrial gene
expression. In addition to decreased complex I, IV and V subunit
expression, ablation of Foxo also causes a profound decrease of
Cyb5r3. The latter is likely a Foxo target40. Cyb5r3 mutations in
humans cause methemoglobinemia40. The membrane-bound
form of Cyb5r3 localizes to mitochondria and endoplasmic
reticulum, where it catalyses desaturation and elongation of fatty
acids, as well as cholesterol biosynthesis. Cyb5r3 generates
reducing equivalents NADþ and NADPþ , and utilizes malonyl
CoA and NADPH to make 18:1, 20:1 and 18:0 fatty acids
in ratios of 65:20:15. Cyb5r3-deficient cells have decreased
NADþ /NADH ratios, mitochondrial respiration, ATP
production and mitochondrial electron transport. This results
in higher oxidative stress and senescence40.
Cyb5r3 is a striking candidate as a b-cell failure gene. One can
envision that in the context of already impaired mitochondrial
complex I, IV and V function in ALDHþ cells, the drop in
Cyb5r3 would result in the additional loss of NADH and NADPH
reductase activity at the level of complex III, decreasing levels of
reduced cytochrome B and C. This may lead to a drop in NADþ
levels to the point where glycolysis is effectively stalled for lack of
reducing equivalents. Consistent with this idea, knockout of the
related isoform, Cyb5r4, in mice causes early-onset b-cell failure
independent of peripheral insulin sensitivity41. In yeast, the
Cyb5r3 ortholog NQR1 extends lifespan in a Sirt1-dependent
manner and increases oxidative metabolism48. Mitochondrial
Cyb5r3 activity is increased by calorie restriction48 (a condition in
which b cells oxidize more FA) and decreased by exposure to
elevated glucose levels49.
In addition to its role in complex III function, Cyb5r3
could prevent b-cell failure through its role in fatty acid
synthesis, effectively shunting away excess fatty acyl-CoA from
mitochondria. This would be achieved in part through activation
of the peroxisome proliferator-activated receptor (Ppar) program,
an interesting feature consistent with the paradoxical increase of
Pparg function in metabolically inflexible b cells8. A decrease of
Cyb5r3 levels can lead to fatty acid accumulation in the oxidative
pathway, and worsen mitochondrial stress through formation of
peroxides or other superoxide products50. In this regard, it should
be noted that another gene specifically affected by Foxo knockout
in ALDHþ cells is Elovl6, whose function to increase long-chain
fatty acid synthesis complements that of Cyb5r3. While isolated
knockout of Elovl6 has no apparent detrimental effect in b cells51,
it remains to be seen whether this is also true in the context of the
failing b cell and in the absence (or deficiency) of Cyb5r3.
An additional interesting candidate emerging from the analysis
of Foxo-deficient ALDHþ cells is Bach2. It increases in wild-type
ALDHþ cells, but decreases in Foxo knockout ALDHþ cells
(Fig. 5b). Our interpretation of these data is that Bach2 is induced
by Foxo when the latter undergoes nuclear translocation6,7, and
decreases as Foxo is cleared from b cells. A transcriptional
repressor first identified as a lineage selector of B-lymphocytes52,
Bach2 has emerged as a genetic susceptibility locus in genome-
wide association studies of human type 1 diabetes45,46, and has
been found to protect b cells from apoptosis and oxidative
stress47. In addition, its ability to regulate differentiation in the
haematopoietic lineage52 raises the question of whether it has
similar effects in endocrine cells, a hypothesis consistent with
Bach2’s ability to drive transcription from Maf sites, which are
known to confer b-cell transcriptional features12,53.
ALDHþ cells are strikingly enriched in selected lncRNAs: 6 of
the 12 top differentially expressed transcripts belong to this
category. At least three of these transcripts have previously been
linked to human b-cell dysfunction: Malat1, Meg3 and Kcnq1ot1.
Malat1 is encoded in an enhancer cluster associated with
b-cell-specific transcription factors54. Meg3 is part of an
imprinted locus that confers susceptibility to type 1 diabetes55
and includes the atypical Notch ligand Dlk1, a negative regulator
of adipocyte differentiation, as well as another gene, Rtl1, whose
transcripts are also among the top enriched mRNAs in ALDHþ
cells (Supplementary Table 1)33. Finally, Kcn1qot1 is part
of an imprinted locus that includes IGF2 and the Beckwith-
Wiedemann locus32 and has been linked to type 2 diabetes
susceptibility56. We don’t know the targets, let alone the
functional consequences, of these changes in the lncRNA
profile of ALDHþ cells, but we envision them to herald
epigenetic changes leading to dedifferentiation.
In sum, the present work advances our understanding of b-cell
failure and provides a series of testable targets to explain
mechanisms of progression from impaired insulin secretion to
cellular dysfunction and dedifferentiation.
Methods
Animal experiments. We performed genotyping as described57,58. Mice were
maintained on a mixed 129J-C57BL/6 background. We derived control genotypes
from the same litters. Owing to the complexity of genotyping the five mutant alleles
(three Foxo alleles, Rosa26-Tomato and Rip-cre), we used different combinations
of Foxo1, 3 and 4 floxed mice without Rip-cre transgene or Rip-cre mice
(Jax Stock #003573) without Foxo floxed alleles as controls59. These mice were
indistinguishable from mixed 129J-C57BL/6 mice in all metabolic tests. All mice
were fed normal chow and maintained on a 12-hour light–dark cycle (lights on at
7:00AM). Sample size calculations were based on the variance observed in prior
experiments8,60. The Columbia University Institutional Animal Care and
Utilization Committee approved all experiments.
Cell lines. We used the mouse insulinoma cell line MIN6, obtained from
American Type Culture Collection, and previously characterized for its ability to
secrete insulin6.
RNA profiling. We performed RNA-sequencing using Illumina library prepara-
tion, Illumina 2000/2500 sequencing instrument, and standard bioinformatics. We
determined differential expression by statistical testing based on negative binomial
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distribution using ‘DESeq’ package of the R software. We visualized transcript
reads with Integrative Genome Viewer (Broad Institute), and performed pathway
analyses with Ingenuity Pathway Analysis (Ingenuity Systems).
Fluorescence-activated cell sorting. We isolated islets by collagenase digestion
from 6-month-old Rip-cre Foxo1,3a,4lox/lox;RFP (ROSA-Tomato) and Rip-cre
Foxo1,3a,4þ /þ ;RFPmice (10–20 animals per genotype). Briefly, after clamping the
common bile duct at its entrance to the duodenum, we injected 3ml of M199
medium containing 1mg of collagenase P (Roche Molecular Biochemicals,
Indianapolis, Ind.) per ml into the duct. We removed the pancreas and incubated it
at 37 C for 17min. Thereafter, we added 30ml of ice-cold M199 medium
containing 10% newborn calf serum to stop the reaction. We dispersed the digested
pancreata by pipetting and rinsed twice with 30ml of the same medium. After
filtering the tissue suspension through a Spectra-mesh (408 mm; Spectrum
Laboratories, Inc.), we resuspended the digested tissue in 10ml of Histopaque and
overlaid it with 10ml of M199 medium. We centrifuged the sample at 1,700g for
20min, and collected the islets from the interface61. We dispersed the islets using
tryspin digestion, washed twice with cold M199 medium, and incubated cells with
the fluorescent ALDH substrate BODIPY-aminoacetaldehyde (aldeflour) for 1 h
before flow cytometry. Thereafter, cells were applied to a BD Influx sorter and
analysed with a BD LSRII instrument. We gated cells for RFP (red) and aldefluor
(green) fluorescence, yielding RFPALDH (GFP_FITC, PE TR subset 2),
RFPþALDH (GFP_FITC, PE TR subset) and RFPþALDHþ cells (GFP_FITC,
PE TR subset 1). We obtained three sub-populations: RFPALDH (non-b cells),
RFPþALDH (b cells) and RFPþALDHþ (ALDH-positive b cells).
Immunoblot and immunohistochemistry. We performed immunoblotting and
immunohistochemistry as previously described7. We used the following antibodies:
rabbit primary antibodies to FoxO1 (Santa Cruz, 1:100, Cell Signaling),
Somatostatin (DAKO, 1:2000), Aldh1a3 (Novus, 1:100), Neurog3 (Beta Cell
Biology Consortium, 1:100) and MafA (Bethyl, 1:200); guinea pig primary
antibodies to Insulin (DAKO, 1:2000) and Glucagon (DAKO, 1:1000) and Pdx1
(Millipore, 1:100); sheep primary antibody to Somatostatin (Novus, 1:200); goat
primary antibodies to Pancreatic Polypeptide (Novus 1:500), Somatostatin
(Chemicon, 1:250), Nkx6.1 (Santa Cruz, 1:100) and L-Myc (R&D, 1:100); and
mouse primary antibodies to Aldh1a3 (LSBio, 1:100) and Glucagon (Sigma,
1:500; ref. 57).
Mitochondrial function. We used the XF24-3 respirometer (Seahorse Bioscience)
with 24-well plates. We used the F1F0 ATP synthase inhibitor oligomycin to assess
uncoupling, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) to
estimate maximum respiration, and rotenone to measure non-mitochondrial
respiration62.
RNA measurements. We used standard techniques for mRNA isolation and
quantitative PCR. PCR primer sequences have been published7.
Statistical analyses and general methods. Sample sizes were estimated from
expected effect size based on previous experiments. No randomization or blinding
was used. We present data as means±s.e.m. We used two-tailed Student’s t-test,
one-way analysis of variance (ANOVA) or two-way ANOVA for data analysis, and
the customary threshold of Po0.05 to declare statistically significant differences.
Data availability. The RNA sequencing data that support the findings of this
study have been deposited in the NCBI Gene Expression Omnibus as GSE78966.
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